Allarity Therapeutics (ALLR) AI Stock Analysis

• Market Cap: $12.11M
• Dividend Yield: N/A
• Average Volume (3M): 533.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: N/A
• EPS Growth: 99.43%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 15,079,572
• 10 Day Avg. Volume: 396,899
• 30 Day Avg. Volume: 533,654
• PEG Ratio: <0.01
• Price to Book (P/B): 1.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.17
• Enterprise Value/Market Cap: 0.37
• Enterprise Value/Revenue: 20.11
• Enterprise Value/Gross Profit: -4.51K
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 28 Underperform
• Price Target: ―

Allarity Therapeutics' overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.

Allarity Therapeutics Business Overview & Revenue Model

Company Description

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Allarity Therapeutics, Inc. generates revenue primarily through strategic partnerships and licensing agreements with other pharmaceutical companies. These collaborations often involve upfront fees, milestone payments, and royalties on future sales of licensed products. The company's revenue model is heavily dependent on advancing its clinical pipeline and securing partnerships for drug development and commercialization. Additionally, Allarity may receive funding through grants and research collaborations aimed at supporting its innovative DRP technology and associated drug development efforts.

Allarity Therapeutics Financial Statement Overview

Summary

Allarity Therapeutics faces significant financial challenges, with no revenue and consistent operational losses. The balance sheet shows low debt but weak equity, indicating financial instability. Negative operating and free cash flows highlight poor cash generation and reliance on external financing.

Income Statement

The company has reported no revenue over several years, indicating a lack of commercialized products. Net income has been consistently negative, reflecting ongoing operational losses. EBIT and EBITDA margins are also negative, highlighting inefficiencies in cost management and operations.

Balance Sheet

The company has low debt levels, which is a positive aspect. However, the equity position has been weak, with negative equity in recent periods, indicating financial instability. The equity ratio has also been declining, suggesting a decrease in asset financing through equity.

Cash Flow

Operating cash flow has been consistently negative, indicating poor cash generation from operations. Free cash flow growth is nonexistent due to persistent negative cash flow. Heavy reliance on financing activities for cash inflow suggests potential liquidity risks.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-1.00K	0.00	-37.00K	-120.00K	-106.00K	-86.00K
	EBIT
-26.04M	-27.24M	-17.93M	-34.46M	-26.56M	-9.23M
	EBITDA
-23.93M	-27.24M	-12.08M	-17.24M	-25.91M	-6.01M
	Net Income Common Stockholders
-23.97M	-24.52M	-11.90M	-16.06M	-26.65M	-5.07M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
25.20M	19.53M	166.00K	2.03M	19.55M	298.00K
	Total Assets
29.73M	22.65M	11.86M	14.54M	49.63M	33.40M
	Total Debt
0.00	1.35M	1.30M	3.73M	1.09M	1.79M
	Net Debt
-25.20M	-18.18M	1.13M	1.71M	-18.47M	1.49M
	Total Liabilities
11.06M	10.84M	14.61M	12.65M	30.85M	6.55M
	Stockholders Equity
18.67M	11.81M	-2.75M	1.89M	18.78M	26.85M
Cash Flow		Free Cash Flow
-18.85M	-17.65M	-12.74M	-16.84M	-15.05M	-7.25M
	Operating Cash Flow
-18.55M	-17.35M	-12.74M	-16.82M	-15.05M	-7.25M
	Investing Cash Flow
-298.00K	-298.00K	0.00	791.00K	1.00M	-3.00K
	Financing Cash Flow
46.55M	36.79M	10.99M	-1.31M	33.82M	6.03M

Allarity Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLR, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 0.93, below the 50-day MA of 0.95, and below the 200-day MA of 1.40, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 36.81 is Neutral, neither overbought nor oversold. The STOCH value of 39.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALLR.

Allarity Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
SLGL	51 Neutral	$20.95M	―	-49.39%	―	473.46%	62.25%
LPCN	48 Neutral	$16.67M	650.59	-24.89%	―	10081.34%	―
BIVI	38 Underperform	$21.17M	―	-93.23%	―	―	66.72%
CLDI	37 Underperform	$10.92M	―	354.78%	―	―	64.19%
EDSA	35 Underperform	$13.48M	―	-58.78%	―	―	-126.54%
ALLR	28 Underperform	$12.11M	―	-383.73%	―	―	99.43%

Allarity Therapeutics Corporate Events

Allarity Therapeutics Restructures Board of Directors

On April 16, 2025, Allarity Therapeutics, Inc. restructured its Board of Directors to achieve a more balanced membership among its classes by moving Thomas H. Jensen from Class I to Class III. This change was made to ensure continuity in board service, with Mr. Jensen’s term now expiring in 2028. Additionally, the company announced that its 2025 annual meeting of stockholders will be held on June 13, 2025, with a record date set for April 16, 2025. The meeting date was advanced by more than 30 days from the previous year’s anniversary, prompting the company to file a Current Report to inform stockholders and outline the submission deadlines for stockholder proposals and nominations.

Spark’s Take on ALLR Stock

According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.

Allarity Therapeutics faces substantial financial challenges, with no revenue and consistent operational losses, which weigh heavily on its stock score. Technical indicators provide a neutral outlook without strong trends, and valuation is difficult due to negative earnings. These factors combine to result in a low score, highlighting significant risks for investors.

To see Spark’s full report on ALLR stock, click here.